Navigation Links
Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Date:10/14/2008

ng months."

About REG1 Anticoagulation System

The REG1 system consists of the first specific, direct-acting anticoagulant controllable by a matched reversal agent. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), put patients at a high risk for therapy-related bleeding complications. REG1 is being developed initially to increase safety and therapeutic flexibility as well as to improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched reversal agent. The anticoagulant component, RB006, is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits factor IXa, a protein that is critical to blood coagulation. The reversal agent, RB007, is a complementary nucleic acid that specifically binds to and neutralizes RB006. The amount of RB007 administered allows physicians to rapidly fine tune the pharmacodynamic effect of RB006, from slight reduction in anticoagulation all the way to complete reversal.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by a specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and fine tune each product's therapeutic effect. This control and flexibility allows physicians to meet the individual needs of each patient independent of the setting. Regado initially is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles.

Current i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
6. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... -- LifeScienceIndustryResearch.com announces Global Angiographic X-ray ... pages along with 8 company profiles added to ... 2015 Market Research Report on Global Angiographic X-ray ... report on Global Angiographic X-ray System market.  For ... basic information including definition, classification, application, industry chain ...
(Date:3/1/2015)... WASHINGTON , March 1, 2015  USPlabs ... of the following and states that media reports ... false: On Saturday, February 28, 2015, ... issued a Public Notification on the contamination of ... Super Thermogenic (referred to below as "OEP") with ...
(Date:2/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a leading ... pharmaceutical, biotechnology, and medical device industries with operations in ... United States , congratulates our partner TaiMed Biologics ... for ibalizumab (TMB355). The FDA designates a drug as ... in combination with one or more other drugs, to ...
Breaking Medicine Technology:Global Angiographic X-ray System Industry Research Report 2Global Angiographic X-ray System Industry Research Report 3Global Angiographic X-ray System Industry Research Report 4Global Angiographic X-ray System Industry Research Report 5OEP Product Is Counterfeit 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2
... 2011 Raylene Riha and her husband, Michael, filed ... Johnson, Inc. seeking compensation for injuries caused by failures ... that have been recalled.  John David Hart of the ... Texas, is the attorney representing Raylene and Michael Riha ...
... (Tianjin) Co. Ltd, a leading research-based contract manufacturer of advanced ... the U.S. and China, is pleased to announce the recent ... Assurance as of March 1, 2011. Mr. ... the pharmaceutical industry (early and late stage), in quality assurance ...
Cached Medicine Technology:Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman 2Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance 2
(Date:3/1/2015)... March 01, 2015 Ticket Down is a ... Chicago at Soldier Field. Deadheads have been anxiously ... January. , Grateful Dead was formed 50 years ago back ... together as one until the untimely death of Jerry Garcia ... different genres including blues, reggae, rock, bluegrass, folk, space rock ...
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:3/1/2015)... 2015 CrossFit Attollo is a CrossFit gym ... a special discount to new members. Now through the ... three month contract will receive their fourth month half off. ... members $440. The three month contract is only $264, ... the fourth month comes in at only $55. The special ...
(Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
(Date:2/28/2015)... With their commitment to achieving physical ... additional exercise to their already robust library of oblique ... commonly known as, is often performed on a stationary ... in a relatively safe manner and can be performed ... full description of “Rope Pulls” is located in the ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... last 25 years, in New York, there has been a ... has increased. Researchers at the University of Texas, have analysed ... between 1981 and 1999.// They find there has been a ... 2.0 cases per 150,000 population to 12.2 per 100,000. For ...
... some valuable advice on how to make sure your vitamin ... and teeth, and helps prevent osteoporosis and any bone related ... vitamin D.// Just10 to 15 minutes of natural sunlight three ... factors can reduce sunlight exposure, such as windows, sunscreen, smog ...
... at the critical care centre felt that, everyone should ... response to infection. Sepsis occurs when the body over-reacts ... is associated with cancer but it can attack anyone.// ... pancreatic and prostate cancer together, and is the leading ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... many people with firm spiritual beliefs find it easier to ... relatives and friends of patients attending a hospice for terminal ... strong spiritual beliefs helped these people cope when their loved ... belief reported steady progress in coming to terms with their ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
Cached Medicine News:
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
... we believe that the trocar should be ... instrument precision and speeding the process. So ... trocar that meets the needs of the ... Xcel - The only trocar that affords ...
Medicine Products: